基于炎症标志物滴定口服糖皮质激素治疗重症哮喘的随机对照试验
这项概念验证性前瞻随机对照试验在澳大利亚纽卡斯尔招募32例重症未控制哮喘成人,比较基于血嗜酸性粒细胞计数与FeNO复合评分调整口服糖皮质激素(OCS)剂量的生物标志物管理(BBM)与标准最佳实践(SBP)。12个月内BBM组至首次重度急性发作的中位时间更长但无统计学意义,需急诊就诊的患者比例显著降低,两组累积OCS剂量无差异。
要点
- 基于血嗜酸性粒细胞计数与FeNO调整OCS剂量在临床可行
- BBM组需急诊就诊比例显著低于SBP组
- 两组重度急性发作率与累积OCS剂量无显著差异
核心结论
- 使用血嗜酸性粒细胞计数和FeNO调整OCS的治疗算法在临床环境中可行,并降低了急诊就诊的比值比。
- 该结果支持未来进一步研究以优化OCS的使用。
研究设计与样本
- 概念验证性前瞻随机对照试验,纳入成人重症未控制哮喘患者32例,BBM组17例、SBP组15例。
- 研究在澳大利亚纽卡斯尔Hunter医学研究所进行,参与者对分组设盲。
- BBM组依据由血嗜酸性粒细胞计数和FeNO组成的复合生物标志物评分调整OCS剂量,SBP组采用标准最佳实践。
- 共同主要结局为12个月内重度急性发作次数和至首次重度急性发作时间。
主要发现
- BBM组至首次重度急性发作中位时间长于SBP组但无统计学意义(295 vs 123天,Adj. HR 0.714;95%CI 0.25至2.06;p=0.533)。
- BBM组相对SBP组重度急性发作的相对风险为0.88(Adj.;95%CI 0.47至1.62;p=0.675),年均发作率分别为1.2和2.0。
- BBM组需急诊就诊的患者比例显著降低(OR 0.09,95%CI 0.01至0.91;p=0.041)。
- 两组累积OCS剂量无差异。
临床怎么用
- 在重症哮喘管理中可考虑用血嗜酸性粒细胞计数与FeNO复合评分指导OCS剂量调整以减少急诊就诊。
- 该策略未显著减少重度急性发作或降低累积OCS剂量,需进一步研究优化。
局限性
- 样本量小(n=32),为概念验证性研究。
- 至首次重度急性发作时间与发作风险差异无统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Biomarkers are used to select biologic therapies for patients with severe asthma, but not to regularly adjust therapy, especially oral corticosteroids (OCS). OBJECTIVE: Our goal was to test the efficacy of an algorithm to guide the titration of OCS using blood eosinophil count and fraction of exhaled nitric oxide (FeNO) levels. DESIGN, PARTICIPANTS, INTERVENTIONS AND SETTING: This proof-of-concept prospective randomised controlled trial assigned adult participants with severe uncontrolled asthma (n=32) to biomarker-based management (BBM) where OCS dose was adjusted based on a composite biomarker score comprised of blood eosinophil count and FeNO, or a standard best practice (SBP) arm. The study was conducted at the Hunter Medical Research Institute, Newcastle, Australia. Participants were recruited from the local Severe Asthma Clinic and were blinded to their study allocation. MAIN OUTCOME: The coprimary outcomes were number of severe exacerbations and time to first severe exacerbation assessed over 12 months. RESULTS: There was a longer median time to first severe exacerbation with BBM, although not significant (295 vs 123 days, Adj. HR: 0.714; 95% CI: 0.25 to 2.06; p=0.533). The relative risk of a severe exacerbation in BBM (n=17) vs SBP (n=15) was 0.88 (Adj.; 95% CI: 0.47 to 1.62; p=0.675) with a mean exacerbation rate per year of 1.2 and 2.0, respectively. There was a significant reduction in the proportion of patients requiring an emergency department (ED) visit using BBM (OR 0.09, 95% CI: 0.01 to 0.91; p=0.041). There was no difference in the cumulative OCS dose used between the two groups. CONCLUSION: A treatment algorithm to adjust OCS using blood eosinophil count and FeNO is feasible in a clinical setting and resulted in a reduced odds of an ED visit. This warrants further study to optimise the use of OCS in the future. TRIAL REGISTRATION NUMBER: This trial was registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12616001015437).
引用
- Ramsahai, Simpson, Cook, et al. Randomised controlled trial for the titration of oral corticosteroids using markers of inflammation in severe asthma. Thorax. 2023. PMID: 36948587. doi:10.1136/thorax-2021-217865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。